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Abstract 14 Cryptococcosis is a globally distributed invasive fungal infection caused by 15 species within the genus Cryptococcus that presents substantial therapeutic 16 challenges. Although natural human-to-human transmission has never been 17 observed, recent work has unveiled multiple virulence mechanisms that allow 18 cryptococci to infect, disseminate within and ultimately kill their human host. In 19 this Review, we describe these recent discoveries that illustrate the intricacy of 20 host-pathogen interactions and reveal new details about host immune responses 21 that either help protect against disease or increase host susceptibility. In 22 addition, we discuss how this improved understanding of both the host and the 23 pathogen informs potential new avenues for therapeutic development. 24  25 Cryptococcosis has been recognized since 1894, when the pathologist Otto Busse 26 and physician Abraham Buschke jointly identified Cryptococcus as the cause of a 27 chronic granuloma of the tibial bone in a 31-year-old woman. However, human 28 cryptococcosis only became recognized as a major health threat with the onset of 29 the AIDS pandemic in the 1980s, in which these fungal infections became a 30 common AIDS-defining illness in patients with catastrophically reduced T-cell 31 function (Box 1). Although cryptococcosis is predominantly a disease of 32 immunocompromised patients, a recent outbreak of cryptococcosis in otherwise 33 healthy individuals in North America and Canada (now known as the Pacific 34 Northwest Outbreak) has focused attention on the capacity of some lineages of 35 the pathogen to act as primary pathogens (see below).   36 Since its identification, cryptococcosis has been attributed to a single 37 fungal species, Cryptococcus neoformans. However, improved molecular methods 38 led to a previous variety, Cryptococcus neoformans var. gattii, being classified as a 39 novel species, Cryptococcus gattii, in 20021. More recently, whole-genome 40 sequencing-based analyses have highlighted the complex evolutionary history of 41 this group (Box 2) and led to a proposal to further split C. neoformans into two 42 species (C. neoformans and Cryptococcus deneoformans) and C. gattii into a total 43 of five species (C. gattii, Cryptococcus bacillisporus, Cryptococcus deuterogattii, 44 
Cryptococcus tetragattii and Cryptococcus decagattii)2. However, as detailed 45 biological comparisons between these five species have not been yet undertaken, 46 
we have adopted the simpler distinction into the two species C. gattii and C. 47 
neoformans throughout this article. 48  49 
Cryptococcus transmission and disease onset   50 In the environment, cryptococci reside in diverse ecological niches (Box 3). Both 51 
C. neoformans and C. gattii are abundant in decaying material within hollows of 52 various tree species, although C. gattii has been suggested to favour trees with 53 waxier cuticles (such as Pseudotsuga menziesii) 3, 4. Furthermore, C. neoformans 54 is globally distributed, whereas C. gattii has classically been viewed as a tropical 55 or subtropical fungus. However, increased surveillance has now identified 56 environmental reservoirs for C. gattii in the Northern USA, Canada and Northern 57 Europe, indicating that this species may also have a wider ecological range than 58 previously recognized.   59 
C. neoformans is particularly abundant in avian excreta4,5 and its 60 association with feral pigeons could be a major source of infection in densely 61 populated urban areas. In addition, both C. neoformans  and C. gattii are able to 62 survive and replicate within free-living amoebae and soil nematodes and it is 63 possible that these alternative hosts may have an important role in determining 64 the distribution and virulence of different cryptococcal lineages around the 65 world (Box 3).   66 With the exception of very rare iatrogenic6 or zoonotic7 transmission 67 events, naturally acquired cases of cryptococcosis are believed to start with 68 inhalation of fungal cells from the environment. Within the lung, Cryptococcus 69 species can cause pneumonia in immunosuppressed patients, but in 70 immunocompetent hosts the fungal cells are either cleared by the immune 71 system or establish an asymptomatic latent infection. Upon subsequent 72 immunosuppression, this latent infection can then disseminate to other tissues, 73 most notably the central nervous system (CNS). Once established within the CNS, 74 cryptococcosis causes an overwhelming infection of the meninges and brain 75 tissue that is frequently accompanied by raised intracranial pressure; without 76 rapid and effective treatment, CNS infection is invariably fatal. Despite intensive 77 investigations, it remains unclear whether reactivation and dissemination of 78 long-term latent pulmonary infection is a more important cause of 79 
cryptococcosis in patients than de novo acquisition from the environment, but 80 experiments in animal models indicate that both routes are capable of causing 81 lethal disease.   82 Exposure to C. neoformans is common in humans, as most individuals 83 produce antibodies against this fungal species by school age8. During active 84 growth, cryptococcal cells are too large to penetrate deep into the human lung 85 and thus the initial inoculum is believed to comprise either desiccated cells or 86 spores. The relative contribution of these two cell types to the burden of disease 87 remains unclear, largely due to technical challenges associated with generating 88 and purifying spores. However, recent studies have demonstrated that lethal 89 brain infections can develop from spore inocula, that spores are readily 90 phagocytosed by host immune cells and, interestingly, that rising humidity 91 dramatically increases spore viability9,10,11. Thus, as with other fungal pathogens 92 such as Coccidiodes immitis, environmental conditions may be an important 93 factor in regulating human cryptococcal exposure.   94  95 
Cryptococcal pathogenesis 96 Traditional virulence factors produced by Cryptococcus (such as the capsule and 97 melanin production) and changes in fungal growth due to the host temperature 98 (37°C) have been previously reviewed in great detail (see for example references 99 12,13). Therefore, in this section of the Review, we will focus on recently emerging 100 concepts in cryptococcal pathogenesis. 101  102 
Fungal morphology. Whether derived from spores or yeast cells, upon 103 inhalation into a mammalian host, all cryptococci transition to or maintain a 104 yeast form. When grown under laboratory conditions, Cryptococcus cells are 105 round and 5-7 μm in diameter. However, their cell size, structure, and 106 characteristics can vary dramatically within the host. 107 The best-characterized atypical morphology of Cryptococcus cells is the 108 titan cell14 (Figure 1). Titan cells are greater than 12 μm in diameter (excluding 109 the capsule), polyploid, have highly cross-linked capsules and a thickened cell 110 wall15,16. Recent studies have shown that titan cells contain elevated levels of 111 chitin. This polysaccharide is recognized and cleaved by host chitinases, which 112 
induces a detrimental adaptive immune response (see below) 17. Intriguingly, the 113 polyploidy observed in titan cells enhances genetic adaptation to the stressful 114 host environment, resulting in increased within-host survival 18.  115 In addition to the large titan cells, unusually small cryptococcal cells have 116 also been observed19,20 (Figure 1).  These so-called “drop” or “micro” cells are 117 only 2-4 μm in size, despite having a thickened cell wall, and appear adapted for 118 growth within macrophages. At present, little is known about this cell type, 119 although they appear to be relatively metabolically inactive and therefore may 120 have an important role during the latent stage of disease. 121 In the environment or under laboratory conditions, cryptococci can also 122 grow as hyphae (during sexual reproduction) or pseudohyphae, but (unlike 123 other pathogenic fungi) these morphologies are not seen in human infections 21. 124 Recent studies overexpressing the transcription factor Znf2, a “master regulator” 125 that triggers the transition from yeast to hyphal growth, showed that the hyphal 126 form elicits a robust protective immune response and is readily cleared by the 127 host22,23, perhaps explaining why filamentous morphologies are not seen in 128 mammalian infections. Interestingly, however, hyphal cryptococci are protected 129 from predation by free-living amoebae24 and thus mammalian and amoebal 130 hosts presumably exert opposing selective pressures on this aspect of 131 cryptococcal morphology (with mammalian hosts favouring the existence of the 132 yeast forms and amoebae favouring hyphal forms).  133  134 
Fungal ageing. Even within a clonal infection, not all cryptococcal cells are 135 equal. For example, the age of individual cryptococcal cells has emerged as a 136 factor that impacts survival in the host and subsequent pathogenesis25. Older 137 cells present in the initial infection, referred to as founder cells, are better able to 138 resist phagocytosis and killing by phagocytes and are resistant to antifungal 139 drugs. This increased resistance to phagocyte killing and antifungals is 140 potentially due to changes in cell wall structure 26, and results in the 141 accumulation of founder cells in the brain at a higher frequency than young 142 cells27. 143  144 
Population-wide signals. In bacterial infections, quorum sensing is a well-145 known mechanism that regulates virulence according to population density. 146 Interestingly, emerging data suggest that quorum sensing may also have an 147 important role during cryptococcal pathogenesis. For example, a quorum sensing 148 effect, mediated by an oligopeptide with 11 amino acids, was identified using 149 mutations in the global repressor TUP1. Notably, although TUP1 is present in 150 several species, the quorum sensing effect mediated by this oligopeptide appears 151 only to occur in C. neoformans28. However, more recently a different signaling 152 molecule, pantothenic acid, has been demonstrated to mediate quorum sensing 153 both between different cryptococcal strains and between cryptococci and other, 154 relatively distantly related, fungal species29. The adhesin Cfl1 has also been 155 shown to modulate colony morphology in a paracrine manner30. Activation of the 156 hyphal regulator Znf2 (discussed above) induces expression of this adhesin, 157 some of which is shed into the environment and triggers neighboring cells to 158 activate Znf2, leading to a positive feedback loop. Thus cryptococci may 159 communicate locally using a range of chemical messengers31.  160 Perhaps most unique is the observation that light-sensing pathways may 161 also be important for virulence in Cryptococcus since deletion of either Bwc1 or 162 
Bwc2, which encode two transcription factors that control fungal responses to 163 light, reduces virulence in a murine model of infection32. In the dark, BWC1 and 164 BWC2 bind to DNA and repress genes involved in filamentation. However, upon 165 light activation, they release this inhibition leading to filamentation and 166 upregulation of UV-resistance pathways. Thus, it is possible that an additional 167 function of these two proteins is to detect darkness and prevent inappropriate 168 filamentation within the host, which would induce a potent immune response 169 and pathogen clearance.  170  171 
Host immunity and pathogen subversion  172 One of the most remarkable discoveries of recent years has been the extent to 173 which cryptococci are able to manipulate the host immune response to dampen 174 inflammation, avoid killing by phagocytic cells and ultimately disseminate into 175 the CNS. 176 
  177 
Inflammatory perturbation. In general, environmental fungi trigger a potent 178 inflammatory response upon entry into the human host. By contrast, cryptococci 179 appear to be immunologically inert, driving much lower levels of inflammatory 180 cytokine release in vitro than other human fungal pathogens such as C. albicans33. 181 This immunological masking relies on a variety of pathogen traits (Figure 1).  182 Firstly, the complex carbohydrates glucuronoxylomannan (GXM) and 183 galactoxylomannan (GalXM), which make up most of the cryptococcal capsule, 184 are extensively shed during infection and directly dampen inflammation by 185 suppressing the pro-inflammatory NF-κB pathway and driving down levels of 186 pro-inflammatory cytokines such as TNF34. In addition, emerging data indicate 187 that cryptococcal chitin, and derivatives thereof, can also act to alter host 188 inflammatory responses during infection17. Secondly, Cryptococcus blocks 189 dendritic cell maturation by reducing both MHC class II-dependent antigen 190 presentation and inhibiting the production of the pro-inflammatory cytokines 191 interleukin (IL)-12 and IL-23 35. Lastly, via a series of as-yet poorly characterized 192 steps, cryptococci are able to partially “repolarize” the immune response, at least 193 in mice, from a strong Th1 response towards a weaker Th1 or often a Th2 194 response that is less effective at fungal clearance17,36-38. 195 Collectively, these mechanisms generate an environment that is 196 dominated by anti-inflammatory markers such as IL-4 and IL-33 39,40,41 which, as 197 a consequence, reduce cryptococcal killing by the immune system38,42. Therefore, 198 modulating natural immune responses to cryptococcal infection towards a more 199 pro-inflammatory profile offers one potential avenue for treatment. However, 200 such approaches need to be carefully managed in order to avoid the potentially 201 fatal “immune overreactions” that can accompany overt inflammation, which can 202 be just as life-threatening as the original infection (Box 4). 203 
 204 
Avoidance and escape from phagocytes. Following entry into the lung, the first 205 immune cell typically encountered by cryptococci is a phagocyte such as an 206 alveolar macrophage or dendritic cell. However, cryptococci are predisposed to 207 avoid killing by these cells, due to their long evolutionary history of exposure to 208 environmental amoebae (Box 3).  Several cryptococcal virulence factors such as 209 capsule synthesis, melanization and urease secretion combine to protect the 210 
fungus from the harsh environment within phagocytic cells by neutralizing 211 reactive oxygen species and pH, allowing it to survive and proliferate within such 212 cells (Figure 2)43.  213 More recently, it has also become clear that cryptococci exhibit a 214 remarkable strategy to escape from within phagocytes. This process, which has 215 been labeled vomocytosis or extrusion, involves inducing the fusion of the 216 phagosomal membrane with the plasma membrane, which results in the 217 expulsion of the fungi from the phagocyte44-48. In addition, either this process, or 218 a closely related one, can drive the direct “lateral transfer” of cryptococci 219 between host cells 44,45. However, the underlying mechanisms of both of these 220 remarkable processes remain unknown.    221 Although cryptococci employ several mechanisms to resist phagocytosis 222 (such as through production of titan cells15,49 and the assembly of a thick 223 polysaccharide capsule), fungal uptake by phagocytes can still occur. However, if 224 uptake does occur, cryptococci perturb both phagosome maturation50 and 225 modify the phagosome membrane in order to allow nutrient exchange and 226 ultimately escape from within the host cell51,52. Notably, these effects are 227 dependent on fungal virulence factors such as laccase and phospholipase B1. 228 These enzymes have been classically thought of as having direct structural roles 229 in melanin synthesis and membrane lipid modification, respectively, but the 230 observation that they also mediate escape from phagocytosis suggests that 231 laccase and phospholipase B1 may also have more subtle roles in modifying host 232 signaling events36,53,54.  233  234 
Dissemination and entry into the CNS. A key feature of cryptococcal 235 pathogenesis involves the exit of Cryptococcus from the lungs into peripheral 236 blood circulation and entry into the CNS compartment. The CNS is both an 237 immune privileged site and a highly sterile environment and thus Cryptococcus 238 must have evolved potent methods to traverse the blood-brain barrier (BBB) 239 and subsist in the CNS.  240 There are three proposed mechanisms that Cryptococcus could utilize to 241 penetrate this impervious barrier. First, the yeasts could force their way 242 between the tight junctions of the endothelial cells in a process known as 243 
paracytosis, by using proteases such as Mpr1 to promote transmigration55 244 (Figure 2). Impressively, when the MPR1 gene was introduced into 245 
Saccharomyces cerevisiae, a fungus not normally able to penetrate the BBB, S. 246 
cerevisiae gained the ability to cross endothelial cells in an in vitro transwell 247 assay, although the target of Mpr1 remains unknown. Additional studies utilizing 248 powerful intravital imaging techniques demonstrated that cryptococci cross the 249 BBB by inducing an embolic event in the microvasculature that lines the brain56. 250 In essence, the initial “capture” of yeast within the brain is therefore passive, 251 with the relatively large yeast cells becoming trapped at points where the blood 252 vessel narrows. However, following the initial passive arrest, cryptococcal 253 migration into the brain tissue is an active process, since it occurs only with live 254 fungal cells and is dependent on the secretion of the cryptococcal enzyme 255 urease57. To date, the part played by urease in this process remains enigmatic, 256 although since urease produces ammonia, which is toxic towards mammalian 257 cells, it is possible that urease acts to locally weaken the endothelial vessel wall, 258 facilitating fungal entry. 259 The second mechanism of BBB penetration is transcytosis58 (Figure 2). 260 Hyaluronic acid situated on the surface of the cryptococcal cell binds to CD44 on 261 the luminal endothelium, attaching the fungus to the host cell 59. This binding 262 then induces protein kinase C-dependent actin remodeling in the host cell, 263 leading it to engulf the attached Cryptococcus60. Interestingly, recent work has 264 revealed that the high levels of inositol present in the brain act as a trigger for 265 this process, increasing hyaluronic acid expression in the fungus 61.   266 Finally, Cryptococcus is postulated to cross the BBB by a third method 267 involving “hitchhiking” within host phagocytes, in a process termed the “Trojan 268 Horse” hypothesis (Figure 2). This hypothesis is supported by the observation 269 that depletion of alveolar macrophages in mice significantly reduces 270 cryptococcal dissemination to the CNS62, while infecting monocytes in vitro and 271 transferring the cells into naïve hosts substantially increases cryptococcal 272 accumulation in the brain compared to transferring Cryptococcus directly; both 273 studies support the notion that phagocytes act as fungal carriers that breach the 274 BBB63. Although paracytosis, transcytosis, and Trojan Horse models are all 275 fundamentally different, it is reasonable to conclude that elements of each of 276 
these models are readily observed and likely occur in concert during natural 277 infection.   278 Not much is known about the physiology of Cryptococcus after it has 279 traversed the BBB. However, a recent study of the transcriptome of cryptococcal 280 yeasts isolated from cerebrospinal fluid (CSF) samples of patients offers some 281 clues64. Most notably, Cryptococcus is remarkably metabolically active in the CSF 282 
in vivo, showing strong up-regulation of stress response genes and genes 283 encoding enzymes that are involved in core metabolic processes; this is 284 somewhat surprising, given that the CSF is a relatively nutrient depleted 285 medium. By contrast, Cryptococcus growing in ex vivo CSF does not seem to be 286 metabolically active, suggesting that the permanent cycling of CSF in vivo leads to 287 a significantly higher nutrient content in the CSF than suggested by the analysis 288 of ex vivo samples.  289 The modified fungal metabolism observed within the CSF is likely to have 290 significant implications for pathogenesis. For instance, capsule synthesis is 291 energetically highly demanding and there is a positive correlation between 292 capsular size and severity of clinical disease 65. Therefore, these data suggest that 293 yeasts in a more active metabolic state may drive more aggressive CNS 294 infections. Furthermore, fungal cells in different metabolic states are likely to 295 give rise to different immune responses, which may also impact disease severity. 296 In agreement with this possibility, the presence of a CSF inflammatory response 297 consisting of an interplay of robust Th1 (IFN-γ and IL-6), Th2 (IL-4 and IL-10) 298 and Th17 (IL-17) cytokines has recently been shown to be highly predictive of 299 more rapid clearance of infection and consequently improved survival in 300 patients with HIV-associated cryptococcal meningitis66 (Box 4). 301 
 302 
Division of labour. The extent to which cryptococci can exploit phagocytic cells 303 as a host has been strongly highlighted by the unusual cluster of cryptococcal 304 disease now known as the Pacific Northwest Outbreak67. Although 305 cryptococcosis is typically a disease of immunocompromised hosts, almost all of 306 the human and animal cases within the Pacific Northwest Outbreak were 307 immunocompetent hosts who became infected with near clonal strains of C. 308 
gattii from the VGII lineage. Both the epidemiology and etiology of these 309 
infections differ from “classical” cryptococcosis (typically caused by C. 310 
neoformans in HIV-positive individuals)33,68, which has led to vigorous efforts in 311 order to establish the underlying mechanism driving virulence in the C. gattii 312 VGII lineage.  313 The ability of the C. gattii VGII lineage to establish disease in individuals 314 with a fully functional immune system seems to stem from a capacity to replicate 315 extremely rapidly within host phagocytes (Figure 2), presumably overwhelming 316 the host before adaptive immunity can be triggered69. Recent data has revealed 317 that this rapid proliferation is, in turn, driven by a remarkable “division of 318 labour” mechanism. In response to reactive oxygen species generated by the 319 phagocyte, intracellular cryptococcal cells adopt different fates; some 320 cryptococcal cells cease growth and acquire an unusual morphology 321 characterized by extensive tubularisation of their mitochondria, whereas 322 neighboring cells do not undergo this morphological transition. Notably, via a 323 mechanism that remains unclear, the cells that undergo the morphological 324 switch then protect neighboring cryptococci from the antimicrobial activity of 325 the host phagocyte, enabling these cells to replicate rapidly, maximizing the 326 proliferative capacity of the population as a whole70. These data highlight the 327 
Cryptococcus—phagocyte interaction as a key aspect of infection that may offer 328 powerful opportunities for therapeutic intervention in both C. neoformans and C. 329 
gattii infections. 330  331 
Anti-cryptococcal therapeutics 332 Despite its global distribution, treatment of cryptococcosis remains a major 333 challenge, relying on a limited arsenal of decades-old therapeutic agents. 334 Furthermore, therapeutic outcomes are generally poor and even with 335 amphotericin-based therapy (to target Cryptococcus) and widespread access to 336 anti-retroviral therapy (to target HIV, since most patients are 337 immunocompromised HIV-positive patients), acute (3-month) mortality 338 following cryptococcal meningoencephalitis remains 35-40%, both in resource-339 rich and resource-poor settings71,72.  340  341 
Currently used drugs. Only three classes of antifungal agents are currently used 342 to treat cryptococcosis: polyenes (amphotericin B), azoles (fluconazole) and the 343 pyrimidine analogue flucytosine (5FC) (Figure 3).  344 The cornerstone of treatment of cryptococcal meningoencephalitis is 345 amphotericin B deoxycholate (AmBd), developed in the 1950s, which exerts its 346 fungicidal effect both by binding to ergosterol in the cryptococcal cell wall 347 (generating pores in the cell membrane) and by inducing cell death via oxidative 348 damage 73-75. AmBd is sometimes combined with 5-FC. The mechanism of action 349 of 5-FC is deamination by the fungal enzyme cytosine deaminase into 5-350 fluorouracil (5-FU), which then acts via two pathways: 5-FU can be converted by 351 cellular pyrimidine processing enzymes into 5-fluorodeoxyuridine 352 monophosphate, which inhibits thymidylate synthetase and blocks DNA 353 synthesis; or 5-FU can be converted into 5-fluorouridine triphosphate, which is 354 incorporated into RNA, thereby disrupting protein synthesis and leading to 355 growth arrest. AmBd and 5-FC act synergistically to produce the fastest rates of 356 fungal clearance from CSF76 and combination therapy results in a significant 357 improvement in 10-week survival compared to treatment with AmBd alone77. 358 This combination remains the recommended ‘gold standard’ induction treatment 359 in international treatment guidelines78 but presents significant challenges in 360 resource poor settings, since AmBd must be administered intravenously and has 361 notable toxicities. In addition, neither AmBd nor 5-FC are widely available in 362 countries where cryptococcosis is most prevalent79.  363 To circumvent the problems associated with AmBd and 5-FC combination 364 therapies, the combination of fluconazole with 5-FC (which can both be 365 administered orally) and shorter (1-week) AmBd-based induction treatment is 366 being compared to the standard 2-week induction regimens in a multi-site phase 367 III African trial 80. Fluconazole is being tested because it has good oral 368 bioavailability and excellent CSF penetration; these properties also make it 369 recommendable for maintenance therapy after initial treatment. Fluconazole 370 inhibits the fungal cytochrome P450 enzyme, 14α-demethylase, which is 371 required for conversion of lanosterol to ergosterol, an essential component of 372 the fungal cell membrane. However, fluconazole is as a fungistatic (rather than 373 
fungicidal) making it is less effective at pathogen clearance and not 374 recommended for initial therapy. 375  376 
Drug resistance. Resistance to antimicrobials is a growing issue in infectious 377 disease and cryptococcosis is no exception. While environmental resistance is 378 rare, acquired resistance has been observed with all three classes of antifungals 379 in use against Cryptococcus species. 380 Polyene resistance is uncommon but has been reported in C. neoformans, 381 with mutations in sterol synthesis and therefore alteration of the target site noted 382 in isolates with extensive exposure to AmB 81. For 5-FC, single mutations at 383 varying points along the 5-FU intracellular pathways lead to in vitro and clinical 384 resistance. Therefore, monotherapy with 5-FC is not appropriate due to rapid 385 selection of resistant Cryptococcus leading to treatment failure; the drug is thus 386 always combined with either AmB or fluconazole. Fluconazole, like 5-FC, is 387 fungistatic, making it liable to evolution of secondary resistance during 388 prolonged treatment82. A key mechanism of resistance against fluconazole is the 389 selection of intrinsically resistant cryptococcal sub-populations 83 that carry 390 specific chromosomal disomies 84 and thus overexpress the ERG11 gene (which 391 encodes the fluconazole target enzyme lanosterol-14α-demethylase85) or have 392 enhanced drug efflux by the ATP Binding Cassette (ABC) transporter-encoding 393 gene  C. neoformans AntiFungal Resistance 1 (CnAFR1) 86.  394  395 
New drugs. Given the ongoing high global incidence and mortality from 396 cryptococcal meningoencephalitis, the dearth of drugs, together with toxicity and 397 the potential for development of resistance, there is an urgent need for new 398 drugs. Recent activity in this area has begun to highlight potential routes either 399 for the discovery of novel antifungals or for the repurposing of existing 400 molecules showing anti-cryptococcal activity (Figure 3). 401 An ideal antifungal drug should be fungal-specific, to avoid host cell 402 toxicity; this is challenging, given that fungal cellular processes are more closely 403 related to mammals than those that are targeted by common antimicrobials, 404 such as the ones used to target bacterial pathogens. Furthermore, an ideal 405 antifungal drug should target either a virulence factor or a fungal component 406 
essential for fungal viability. Such a drug should be fungicidal when used alone 407 or when combined with the widely available fluconazole, should have good oral 408 bioavailability (allowing it to be readily administered even in resource-poor 409 settings) and be able to enter cryptococcal niches within the host (such as 410 phagocytes and the CNS).  411 One obvious target of such a drug is the cryptococcal cell wall. 412 Unfortunately, the latest class of antifungals active against the cell wall, the β-413 1,3-D-glucan synthase inhibitors (echinocandins), have no significant anti-414 cryptococcal activity. However, synthesis of another cell wall component, 415 glycosylphosphatidylinositol (GPI)-anchored mannoproteins, is inhibited by the 416 orally-active experimental molecule E1210, which has in vitro activity against 417 
Cryptococcus and other medically-relevant fungi (such as Candida and 418 
Scedosporium species) and is currently in pre-clinical development87.  419 Further along the development pipeline is VT-1129, an orally-available 420 ergosterol synthesis inhibitor which shows good CNS penetration and is 421 fungicidal in murine models of Cryptococcus infection. VT-1129 blocks the 422 activity of CYP51, an essential enzyme in the pathway to produce ergosterol, and 423 is currently entering human clinical trials 88. Also in Phase I trials is the 424 arlyamidine T-2307, which targets the fungal mitochondrial membrane89. T-425 2307 is a fungicidal injectable compound that shows comparable efficacy to AmB 426 in murine models of infection.  427 Given the lack of market forces driving pharmaceutical development for a 428 neglected disease such as cryptococcal meningoencephalitis, an alternative, 429 cheaper and more expedient strategy in drug development is the repurposing of 430 drugs not originally developed for antifungal use. Recently developed high-431 throughput screening techniques have advanced the repurposing effort. One 432 such powerful tool is chemical-genetic profiling, whereby large collections of 433 cryptococcal knockout mutants, for which the function of a particular pathway is 434 compromised, are screened against a library of small molecules90, and the 435 growth behavior of the screened strain (i.e. increased or decreased 436 susceptibility) is then recorded. This technique was recently performed with 437 1448 knockout mutants of C. neoformans and demonstrated distinct differences 438 in drug susceptibility between this species and the model organism 439 
Saccharomyces cerevisiae which, until now, has been the standard choice for such 440 screens90. As proof of principle, this approach has identified a number of 441 molecules that synergize strongly with fluconazole to inhibit ergosterol 442 synthesis in C. neoformans and which are now being further investigated for 443 potential clinical applicability. Moreover, this method has the additional 444 advantage of providing information on the mechanism of action of lead 445 compounds and can therefore identify both potential new drugs and potential 446 new drug targets. 447 A more classical approach is to screen for compounds that trigger fungal 448 lysis (detected by the release of adenylate kinase, a cytosolic enzyme, into the 449 medium) or alter ATP content 91 (a particularly effective approach for identifying 450 compounds that are antifungal under starvation conditions). This strategy has 451 identified a collection of off-patent drugs92 with anti-cryptococcal activity that 452 are additive or synergistic with fluconazole. These include drugs as diverse as 453 amiodarone (a cardiac anti-arrhythmic drug), phenothiazines (widely used 454 antipsychotics) and tamoxifen (an estrogen antagonist used in the treatment of 455 breast cancer). Illustrating the utility of these approaches, tamoxifen in 456 combination with fluconazole, decreased the C. neoformans burden in the brain 457 by ~1 log10 CFU per gram of brain tissue, in a mouse model of infection93. Finally, 458 another candidate that has emerge from repurposing screens is the anti-459 depressant sertraline (also known as Zoloft®), a drug that is fungicidal, has high 460 CNS penetration, and appears to target fungal protein synthesis through an 461 unknown mechanism94. Sertraline is currently being evaluated in combination 462 with AmBd and fluconazole in a phase II/III clinical trial 95. 463  464 
Outlook 465 The last five years have seen a remarkable revolution in our understanding of 466 cryptococcosis. A deeper understanding of the natural ecology and an 467 appreciation of the genetic and phenotypic diversity of this group of pathogens is 468 transforming our understanding of cryptococcal pathogenesis. Meanwhile, huge 469 progress has been made in understanding the host immune response to infection 470 and how this process is hijacked by cryptococci to drive latency, dissemination 471 and proliferation. However, despite these advances, cryptococcosis remains a 472 
major worldwide killer, causing hundreds of thousands of deaths per year and 473 the anti-cryptococcal drug arsenal remains limited. To address this, there is 474 renewed focus on translational research to discover and develop new 475 therapeutic agents and to evaluate new therapeutic strategies in a clinical setting. 476 Whilst progress is being made in this respect, more is urgently required, and 477 advances in understanding of the pathogenesis of Cryptococcus spp offer new 478 opportunities for developing therapeutics beyond the traditional approaches of 479 killing the fungal cell or preventing its replication. In particular, the rapidly 480 expanding understanding of the Cryptococcus-host interface opens up new 481 avenues for potential therapy development; for instance, in modifying host 482 inflammatory responses, augmenting phagocytic clearance of the fungus, 483 disrupting population signaling or preventing migration to the CNS. Together, 484 such approaches offer the hope of significantly reducing the huge global burden 485 of infection and making fatal cryptococcosis a disease of the past.   486  487 
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Box 1. Clinical cryptococcosis.  501 
Epidemiology. Since cryptococci are capable of extended latency within host 502 cells43 and most humans encounter the organism in early childhood8, it has been 503 assumed that most clinical cases represent reactivation of a longstanding, 504 asymptomatic infection (triggered, for instance, by falling CD4+ T-cell counts in 505 HIV-infected individuals). The proportion of clinical disease representing 506 reactivated latent disease versus primary infection is unknown in HIV-positive 507 individuals, but a study in patients with cryptococcosis following solid-organ 508 transplantation found only 52% of infections to be due to reactivation96, 509 suggesting that the classical view of cryptococcosis as a reactivating infection 510 may not be accurate. 511 Emerging data are also highlighting the heterogeneity of cryptococcal 512 disease worldwide, as illustrated by the prevalence of serum cryptococcal 513 antigen (CrAg) in HIV-positive cohorts in different countries (see the figure, 514 which displays the highest recorded prevalence per country). In addition, it is 515 now clear that there is also considerable global heterogeneity in the fungal 516 population structure. For example, C. neoformans var grubii (serotype A) is the 517 predominant global cause of HIV-associated cryptococcal meningoencephalitis, 518 but in China this organism frequently infects apparently immunocompetent 519 hosts97. Similarly, particular lineages of C. neoformans vary both in virulence98-100 520 and in their ability to infect immunocompromised or immunocompetent 521 individuals101.  In the near future, intensive whole genome sequencing efforts for 522 both cryptococcal isolates and affected patients offers the possibility of being 523 able to explain the relative contribution of host and pathogen genotypes 524 underlying these global patterns of disease.    525 
Susceptibility. In contrast to other systemic fungal infections (such as 526 candidiasis), relatively little is known about genetic risk factors for 527 cryptococcosis.  However, recent allelic association studies have shown that 528 apparently immunocompetent individuals with cryptococcosis are significantly 529 more likely to have defects in mannose-binding lectin102 or be homozygous for 530 the “232I” allele of the Fcgamma receptor 2B (FcgR2B)103, although these 531 polymorphisms are relatively common and thus, on their own, are clearly not 532 sufficient to render an individual fully susceptible to cryptococcosis. Therefore, 533 
subtle defects in the innate immune response to fungi may underlie at least some 534 cases of C. neoformans infection in otherwise healthy individuals. Similarly, in 535 HIV-positive patients, allelic variation in a different FcgR, FcgR3A, also correlates 536 with susceptibility104. In this case, individuals with a higher affinity receptor 537 variant are at greater risk of infection, perhaps indicating that efficient uptake of 538 the pathogen may actually aid dissemination and drive more severe disease. This 539 is particularly striking since the same is true from the pathogen perspective; 540 cryptococcal strains that are more avidly phagocytosed drive more aggressive 541 disease and carry a higher risk of death in patients105. Thus, excessive 542 phagocytosis as a result of either host or pathogen variation appears to drive 543 cryptococcal dissemination, strongly supporting the “Trojan Horse” model of 544 pathogen spread (see the main text).     545 
Diagnosis. Diagnosis of cryptococcosis relies on detection either of the organism 546 itself or its shed capsular GXM polysaccharide in serum or CSF. This has been 547 hugely facilitated by the introduction of the point-of-care lateral flow 548 cryptococcal antigen assay, which is cheaper and more sensitive than earlier 549 serological tests106. This test can detect very early dissemination and has 550 facilitated cohort studies across the world, revealing a prevalence of 551 cryptococcal antigens in HIV-infected patients ranging between 2 and 21%. As an 552 increasing proportion of cases of cryptococcal meningoencephalitis are now 553 presenting as “unmasking” of latent infection following therapy (i.e. the 554 appearance of clinical symptoms following immune reconstitution by 555 antiretroviral treatment), wider implementation of a ‘screen-and-treat’ approach 556 is cost effective as a public health intervention and has been demonstrated to 557 reduce mortality in African HIV cohorts in the first year on ART107.  558 
 559 
Box 2: The evolutionary history of cryptococci 560 The two Cryptococcus species, C. gattii and C. neoformans, probably diverged 561 from a common environmental saprophyte ancestor around 30-40 million years 562 ago108,109 (see the figure). For C. neoformans, extensive genetic data now 563 indicates a common origin in sub-Saharan Africa5,110,111. The observation that 564 most non-African C. neoformans populations are near-clonal supports a model in 565 which recombining African populations of cryptococci occasionally dispersed to 566 
other parts of the globe. Coalescence analyses indicate that almost all of these 567 events have occurred within the last 5000 years, suggesting the potential 568 involvement of human or avian migrations in this process5.  569 Probing the origin and diversity of C. gattii has proven more challenging. 570 There is a growing consensus that the evolutionary origins of this species lie 571 within Australia and South America, since most dispersed lineages of C. gattii are 572 near clonal (such as the lineage responsible for the Pacific Northwest Outbreak) 573 but always cluster with Australian and South American isolates during 574 phylogenetic analyses, with an estimated origin within the last 50 thousand 575 years 112-114. A recurrent theme therefore appears to be that local populations of 576 
C. gattii in endemic areas (such as Brazil) undergo continual recombination, 577 which occasionally results in a novel recombinant lineage that disperses and 578 expands rapidly by means of clonal growth (either asexual cell division or same-579 sex mating) 112,113,115.  580 Both species of Cryptococcus have a bipolar mating system in which cells 581 are either mating type a (MATa) or mating type alpha (MATα) (reviewed in 116). 582 Classical mating involves genetic exchange between a MATa and MATα strain, 583 followed by normal Mendelian segregation of alleles. However, both species of 584 cryptococci are also capable of same-sex mating in which two strains of the same 585 mating type are able to exchange genetic material 115,117. In addition, diploid and 586 aneuploid strains are not uncommon118,119, and inter- and intra-species hybrids 587 can be found both in the environment and in patients120,121. Thus the global 588 population structure of these pathogens reflects a complex mix of “diversity 589 generating” recombination and aneuploidy, coupled with highly clonal 590 amplification steps during dispersion events.   591  592 
Box 3: The evolution of virulence in cryptococci 593 Opportunistic pathogens represent an evolutionary enigma: why has natural 594 selection driven the acquisition of often highly specific virulence factors when 595 the majority of the population remain as exclusively environmental organisms 596 for their entire existence? This conundrum is particularly pertinent for 597 cryptococci, which are abundant in the environment and yet are remarkably well 598 suited to survive in a human host.   599 
A compelling hypothesis to resolve this conundrum is that of “accidental 600 pathogenesis”122. This hypothesis proposes that cryptococcal pathogenesis does 601 not result from direct selection for virulence within a mammalian host, but 602 rather by the evolution of traits (which happen to be advantageous in mammals) 603 in response to other selective pressures in both environmental and animal 604 niches. So, for instance, the complex polysaccharide capsule, laccase activity and 605 ability to synthesize melanin, which are all Cryptococcus virulence factors, are 606 likely to offer protection against environmental pressures such as desiccation or 607 exposure to ultraviolet light 123, or aid in the colonization of plant hosts 124. 608 Similarly, cryptococci can replicate not only within vertebrate phagocytes, but 609 also within free-living phagocytic amoebae125 (see the figure). Despite the 610 enormous evolutionary distance between vertebrates and amoebae, many of the 611 mechanisms used by phagocytic white blood cells to kill pathogens (e.g. the 612 generation of reactive oxygen species or secretion of antimicrobial peptides) are 613 identical to those used by amoebae to digest ingested prey. Thus, over millions of 614 years, cryptococci have been selected to evolve strategies that facilitate fungal 615 growth and persistence within amoebae that coincidentally also enable their 616 survival within phagocytes. Such strategies include not only stress-tolerance 617 approaches, such as resistance to reactive oxygen species126, but also elaborate 618 mechanisms to regulate expulsion from host cells46,47. 619 In addition, Cryptococcus has a remarkable ability to perturb adaptive 620 immunity, preventing complete fungal clearance and resulting in latent 621 infections.19,127.  Perhaps the ability to remain latent without perturbing its host 622 is the strongest evidence for host adaptation by Cryptococcus. Since only higher 623 vertebrates have adaptive immune systems, Cryptococcus species probably 624 evolved these properties under the selective pressures of reptilian, avian or 625 mammalian hosts within the environment, which also explains the diverse range 626 of animals that can succumb to cryptococcosis.  627 Taken together, these observations suggest that interactions with both 628 soil microorganisms (such as amoebae and nematodes) and vertebrates likely 629 have a critical role in the virulence potential of Cryptococcus (reviewed in 128). 630 Intriguingly, laboratory studies have shown that selection pressure by amoebae 631 can rapidly select for resistant, pseudohyphal forms of cryptococci23. These 632 
forms are attenuated in mammalian hosts and consequently frequently revert to 633 yeast upon entry into a vertebrate host. Thus, rapid microevolutionary events 634 may have an important role in driving cryptococcal pathogenesis in different 635 hosts. 636 The paradigm of ‘accidental pathogenesis’ extends beyond cryptococci to 637 other fungal129 and even bacterial pathogens130, such as Aspergillus, Blastomyces 638 and Legionella species, and highlights two important issues. Firstly, as pathogens 639 adapt to changing environments due to global warming, we may see additional 640 instances of “accidental pathogenesis” through the selection of new traits that 641 promote both environmental survival and pathogenesis in humans. Secondly, we 642 should be alert to the fact that changes in human behavior and habitat use (e.g. 643 increased tourist access to remote rainforest or desert areas) may expose us to 644 novel potential pathogens that have been predisposed to infection via selection 645 through environmental predators.   646 
 647 
Box 4.  Host immunity: too little or too much? 648 Poor inflammatory responses to cryptococci, such as those in patients with 649 advanced HIV infection, lead to life-threatening meningoencephalitis. 650 Consequently, immune profiling of patient peripheral T-cell responses and CSF 651 cytokines has shown that those mounting a pro-inflammatory immune response 652 are more likely to clear the pathogen and survive infection66. Moreover, 653 augmenting pro-inflammatory immune responses using adjunctive IFN-γ 654 improves fungal clearance131. Conversely, individuals producing anti-cytokine 655 antibodies that interfere with appropriate inflammatory responses are known to 656 be at enhanced risk of infection132.   657 Although a potent immune response to Cryptococcus is clearly essential 658 for fungal clearance, too strong a response can also be harmful. For instance, a 659 low level of anti-inflammatory activity driven by both Th2 and regulatory T 660 cells133,134 prevents complete immune paralysis. This is also the case for the 661 classical antifungal cytokine IL-17, which is essential for resistance to 662 cryptococcosis135 but whose effects must also be regulated by IL-23 in order to 663 prevent damage to the host due to excessive inflammation136. Thus a “successful” 664 immune response to cryptococcal infection appears to be a complex blend of 665 
Th1, Th2 and Th17 responses, which must be counter-regulated to prevent 666 either runaway fungal growth or damaging levels of inflammation.  667 This critical role for “restraining” inflammatory signaling is particularly 668 highlighted by the problem of immune reconstitution inflammatory syndrome 669 (IRIS). This life-threatening inflammatory reaction occurs in some HIV-infected 670 patients during antiretroviral therapy (ART) and is attributable to the newly 671 reconstituted immune system “overreacting” to residual pathogen antigen. 672 Consequently, the timing of clinical intervention is critical; early introduction of 673 ART is important to restore cell-mediated immunity, but if introduced too early 674 (during the initial 2 weeks following induction of antifungal treatment) at a time 675 of high fungal load, the risk of death is increased137. Development of IRIS is 676 particularly likely in patients whose initial pro-inflammatory response to 677 cryptococcal infection is poor, resulting in high residual antigen burden138. 678 Coupled with an exaggerated baseline CNS chemokine response, this results in 679 aberrant CNS immune responses following ART initiation, resulting in IRIS. 680 Excessive inflammation can also occur following withdrawal of immune 681 suppression in solid organ transplant recipients, as well as in apparently 682 immunocompetent patients. In such situations, steroids are often administered 683 alongside antifungals. It remains unclear, however, whether steroids are 684 beneficial in other contexts: a multi-centre clinical trial to address this issue 685 (investigating the effect of adjunctive dexamethasone in patients with HIV-686 associated cryptococcal meningoencephalitis) has been terminated early and 687 results are awaited139. 688   689 690 
  691 
Figure 1.   Inflammatory signaling in response to cryptococcal infection.  692 Cryptococci inevitably shed microbial molecules that contain pathogen 693 associated molecular patterns (PAMPS). Such fungal molecules are typically cell 694 wall or capsular components such as chitin, β-glucan or glucuronoxylomannan 695 (GXM), which are detected by immune sentinel cells, most notably dendritic cells 696 (DCs). DC activation then summons T-cell help, inducing CD4+ T-cells to secrete 697 cytokines that induce a T helper cell 1 (Th1) response (such as interleukin (IL)-698 12 and IL-23). Th1 cells produce pro-inflammatory cytokines (such as IFN-γ) 699 that ultimately control fungal infection. However, some fungal PAMPs can 700 influence DC activation, including modulating the levels of MHC-II or NF-kB 701 signaling. This leads to the generation of a Th2 response (mediated by the 702 production or cytokines such as IL-4 and IL-33); this anti-inflammatory 703 environment impacts the ability of macrophages to mediate fungal clearance.  704  705 
Figure 2.  Infection establishment and dissemination within the human 706 
host. Cryptococcal cells typically enter the human host through the lung. Here 707 they are recognized by patrolling phagocytes but can avoid uptake either by 708 growing into very large “Titan” cells, or by relying on the antiphagocytic 709 properties of the fungal capsule. If uptake occurs, however, cryptococci are able 710 to survive and persist within phagocytes. For most strains, a failure in host 711 immune function is then required to allow intracellular proliferation. However, 712 the unusual Pacific Northwest Outbreak (PNO) strains of C. gattii can proliferate 713 within immunocompetent host cells by exploiting a poorly-characterized 714 “Division of Labour” mechanism: in response to reactive oxygen species 715 generated by the phagocyte, some cryptococcal cells acquire an unusual 716 morphology characterized by extensive tubularisation of their mitochondria, 717 which increases survival of neighboring cells (via a mechanism that remains 718 unclear). Cryptococcus proliferation within phagocytes ultimately leads either to 719 host cell lysis or to a novel non-lytic escape mechanism termed vomocytosis. 720 Upon replication in the lung, cryptococci are able to disseminate to other tissues, 721 including the central nervous system (CNS). Entry into the CNS can occur in 722 three ways: by squeezing between host endothelial cells (paracytosis), which 723 
involves the fungal protease Mpr1; by moving directly through endothelial cells 724 (transcytosis), in a process that is mediated by hyaluronic acid in the fungal 725 capsule and the host receptor CD44; or by “hitching a ride” within migrating 726 phagocytes, in a process termed the “Trojan horse” hypothesis.  727  728 
Figure 3: Current and future therapies for cryptococcosis. Schematic 729 representation of a cryptococcal cell, showing key current and potential 730 therapeutic targets and examples of antifungal drugs acting at each site. Drugs in 731 current clinical use are shown in red, novel drugs are shown in blue and 732 repurposed drugs are shown in green. The three classes of antifungal agents 733 currently used to treat cryptococcosis are polyenes (amphotericin B), azoles 734 (fluconazole) and the pyrimidine analogue flucytosine (5-FC) Amphotericin B 735 deoxycholate (AmBd) acts by binding to ergosterol in the cryptococcal cell wall, 736 generating pores in the cell membrane, and by inducing cell death via oxidative 737 damage. 5-FC is deaminated by the fungal enzyme cytosine deaminase into 5-738 fluorouracil (5-FU), which then inhibits thymidylate synthetase and blocks DNA 739 synthesis or is converted into 5-fluorouridine triphosphate, which is 740 incorporated into RNA and disrupts protein synthesis. Fluconazole inhibits the 741 fungal cytochrome P450 enzyme, 14α-demethylase, which is required for 742 conversion of lanosterol to ergosterol, an essential component of the fungal cell 743 membrane. E1210 inhibits the synthesis of the cell wall component 744 glycosylphosphatidylinositol (GPI)-anchored mannoproteins. VT-1129 blocks 745 the activity of CYP51, an essential enzyme in the pathway to produce ergosterol. 746 The arlyamidine T-2307 targets the fungal mitochondrial membrane. Tamoxifen 747 (an estrogen antagonist used in the treatment of breast cancer) targets 748 calmodulin and the anti-depressant sertraline appears to target fungal protein 749 synthesis through an unknown mechanism. 750  751 752 
GLOSSARY 753 
Pacific Northwest Outbreak – an unusual cluster of cryptococcal disease in 754 otherwise healthy (rather than immunocompromised) individuals.  First 755 identified on Vancouver Island, British Columbia, in 1999 (and hence originally 756 called the Vancouver Island Outbreak), both the causative organism and cases of 757 human and animal disease have now expanded into mainland Canada and the 758 northwestern USA, prompting a renaming of the outbreak. 759  760 
Iatrogenic – caused by medical treatment.  For instance, infections due to 761 contaminated surgical instruments. 762  763 
Zoonotic – a disease transmitted from non-human animals to people 764  765 
Diploid – having two homologous sets of chromosomes, one from each parent 766  767 
Aneuploid – having an ‘unbalanced’ set of chromosomes; for instance, having only 768 a single copy of one chromosome in an otherwise diploid genome. 769  770 
Polyploid – having multiple (more than two) sets of homologous chromosomes 771  772 
Founder – the initial (small) group of individuals that seeds a new population.  773 For instance, the inoculum that starts an infection, or the first individuals to 774 arrive on a new island habitat. 775  776 
Quorum sensing – the regulation of gene expression or behavior in response to 777 changes in the local population size. 778  779 
Paracrine – a signal that acts close to where it is produced; for instance, on 780 neighbouring cells. 781  782 
Filamentation – the growth of an organism by elongation without division.   783  784 
MHC Class II – molecules that are expressed on the surface of professional 785 antigen presenting cells (such as macrophages and dendritic cells) and present 786 extracellular antigens to the immune system to coordinate an immune response 787  788 
Th1/Th2 response – A broad characterization of the differentiation of CD4+ 789 helper T cells (Th). Th1 responses are generally provoked by intracellular 790 pathogens and Th2 responses are typically involved in the elimination of 791 parasitic worms, harmful allergic responses, and dampening of Th1-mediated 792 inflammation.  In the context of cryptococcal infection, Th1 responses are widely 793 thought to be protective and Th2 responses are detrimental. 794  795 
Melanization – the production of the dark, insoluble pigment melanin, which 796 provides protection from high energy radiation and reactive oxygen molecules. 797  798 
Blood-brain barrier – a specialized endothelial barrier that prevents the entry of 799 cells or large molecules into the central nervous system 800 
 801 
Paracytosis – transitioning between tissues by moving between, rather than 802 through, adjacent cells. 803  804 
Transcytosis - transitioning between tissues by moving directly through cells, 805 rather than between adjacent cells. 806  807 
Hyaluronic acid – an abundant, high molecular weight polysaccharide that forms 808 part of the extracellular matrix, particularly in neural tissue. 809  810 
Cerobrospinal fluid (CSF) – a clear fluid produced in the brain which bathes the 811 central nervous tissue and is slowly turned over. 812  813 
Fungistatic – an antimicrobial agent that prevents fungal growth, but does not 814 kill the organism 815  816 
Fungicidal – an antimicrobial agent that kills fungi, rather than simply preventing 817 growth 818  819 
Coalescence analysis – an evolutionary analysis method in which genetic drift is 820 “played backwards” in order to calculate common ancestry of individuals within 821 a population and thereby estimate lineage branch points within an evolutionary 822 phylogenetic tree. 823  824 
Bipolar mating – a system to control sexual reproduction that relies on a single 825 genetic locus at which individual organisms can carry one of two alleles, 826 effectively generating a species with two sexes. 827 
 828 
Regulatory T-cell – a type of T-cell that functions to regulate the immune system, 829 typically by suppressing the function of proinflammatory effector T-cells.830 
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Online Summary 877 
• Cryptococcosis is a widespread opportunistic fungal infection of humans 878 and other animals. 879 
• Cryptococcus species that infect humans likely evolved as “accidental 880 pathogens” in response to environmental selective pressure. 881 
• Recent genomic analyses have highlighted the evolutionary history of 882 
Cryptococcus species and narrowed down the geographical origin of an unusual, 883 hypervirulent outbreak. 884 
• Despite being accidental pathogens, cryptococci display a remarkable 885 ability to manipulate the human immune response in order to facilitate disease 886 establishment and spread. 887 
• Detailed in vivo and in vitro characterization of Cryptococcus species has 888 started to elucidate the details of multiple mechanisms of pathogenesis that 889 likely have important roles in disease severity. These include changes in fungal 890 morphology, interactions with host phagocytes and mechanisms that allow 891 
Cryptococcus to disseminate from the lung to the CNS.  892 
• Renewed efforts to develop improved therapeutic approaches have 893 highlighted potential new drugs and potential new uses for old drugs in the fight 894 against cryptococcal disease. 895  896 
ToC blurb 897 
Recent studies have elucidated multiple virulence mechanisms used by 898 
Cryptococcus to infect, disseminate within and ultimately kill their human host. 899 In this Review, May et al. describe these recent developments in understanding 900 host-fungal interactions, discuss how they affect disease severity and debate 901 current and future therapeutic interventions against cryptococcosis. 902  903 
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